1. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
- Author
-
Peluso, Michael J., primary, Takahashi, Saki, additional, Hakim, Jill, additional, Kelly, J. Daniel, additional, Torres, Leonel, additional, Iyer, Nikita S., additional, Turcios, Keirstinne, additional, Janson, Owen, additional, Munter, Sadie E., additional, Thanh, Cassandra, additional, Nixon, Christopher C., additional, Hoh, Rebecca, additional, Tai, Viva, additional, Fehrman, Emily A., additional, Hernandez, Yanel, additional, Spinelli, Matthew A., additional, Gandhi, Monica, additional, Palafox, Mary-Ann, additional, Vallari, Ana, additional, Rodgers, Mary A., additional, Prostko, John, additional, Hackett, John, additional, Trinh, Lan, additional, Wrin, Terri, additional, Petroplolous, Christos J., additional, Chiu, Charles Y., additional, Norris, Philip J., additional, DiGermanio, Clara, additional, Stone, Mars, additional, Busch, Michael P., additional, Elledge, Susanna K., additional, Zhou, Xin X., additional, Wells, James A., additional, Shu, Albert, additional, Kurtz, Theodore W., additional, Pak, John E., additional, Wu, Wesley, additional, Burbelo, Peter D., additional, Cohen, Jeffrey I., additional, Rutishauser, Rachel L., additional, Martin, Jeffrey N., additional, Deeks, Steven G., additional, Henrich, Timothy J., additional, Rodriguez-Barraquer, Isabel, additional, and Greenhouse, Bryan, additional
- Published
- 2021
- Full Text
- View/download PDF